公开(公告)号：US20120070847A1

公开(公告)日：2012-03-22

申请号：US13128181

申请日：2009-11-05

Applicant: Jan Jensen ,  John Hutton ,  Xiaoling Qu ,  Howard Davidson

Inventor： Jan Jensen ,  John Hutton ,  Xiaoling Qu ,  Howard Davidson

IPC: G01N33/566 ,  C12Q1/02 ,  C07K16/28 ,  C12N5/071 ,  C07H21/04 ,  C07K14/705

CPC classification number: G01N33/56966 ,  C07K14/705 ,  C07K14/70503 ,  C07K16/28 ,  C07K16/2803 ,  C07K2319/30 ,  C12N5/0676 ,  G01N33/5032 ,  G01N33/507 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2800/042

Abstract: The invention is based, in part, on the discovery that a polypeptide, referred to herein as Betacam, is selectively expressed on the surface of pancreatic islet cells, Thus, in one aspect, the invention is directed to compositions comprising Betacam or that can be used to detect Betacam. In another aspect, the invention provides methods of detecting (e.g., non-invasively) pancreatic beta cells from a mammalian cell source. Another aspect of the invention is directed to cellular purification of pancreatic beta cells from a heterogeneous cell source of multiple kinds. In another aspect, the invention provides methods of identifying agents that modulate activity of Betacam-In yet another aspect, the invention provides for improved treatment and diagnosis of diabetes.

Abstract translation: 本发明部分地基于以下发现：本文称为Betacam的多肽在胰岛细胞的表面上选择性表达。因此，一方面，本发明涉及包含Betacam或可以是 用于检测Betacam。 另一方面，本发明提供了从哺乳动物细胞来源检测（例如非侵入性）胰腺β细胞的方法。 本发明的另一方面涉及从多种异质细胞来源的胰腺β细胞的细胞纯化。 另一方面，本发明提供了鉴定调节Betacam-In的活性的试剂的方法。另一方面，本发明提供改善的糖尿病治疗和诊断。